Poseida Therapeutics, Inc.
PSTX · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $64,703 | $130,362 | $31 | $0 |
| % Growth | -50.4% | 417,217.1% | – | – |
| Cost of Goods Sold | $156,772 | $5,172 | $4,552 | $2,586 |
| Gross Profit | -$92,069 | $125,190 | -$4,521 | -$2,586 |
| % Margin | -142.3% | 96% | -14,472% | – |
| R&D Expenses | $156,772 | $152,899 | $137 | $104 |
| G&A Expenses | $37,435 | $37,539 | $36 | $23 |
| SG&A Expenses | $37,435 | $37,539 | $36 | $23 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2,858 | $20 | $0 |
| Operating Expenses | $194,207 | $190,438 | $173 | $127 |
| Operating Income | -$129,504 | -$59,946 | -$141 | -$127 |
| % Margin | -200.2% | -46% | -452.7% | – |
| Other Income/Exp. Net | $6,181 | -$3,512 | $16,437 | -$129,648 |
| Pre-Tax Income | -$123,323 | -$63,458 | -$125 | -$130 |
| Tax Expense | $107 | $544 | -$4,529 | -$2,582 |
| Net Income | -$123,430 | -$64,002 | $4,404 | $2,452 |
| % Margin | -190.8% | -49.1% | 14,097.8% | – |
| EPS | -1.37 | -0.89 | 0.071 | 0.042 |
| % Growth | -53.9% | -1,357.1% | 68.6% | – |
| EPS Diluted | -1.37 | -0.89 | 0.071 | 0.042 |
| Weighted Avg Shares Out | 90,185 | 71,912 | 62,176 | 58,400 |
| Weighted Avg Shares Out Dil | 90,185 | 71,954 | 62,236 | 58,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $3,506 |
| Interest Expense | $8,671 | $6,370 | $3,358 | $4 |
| Depreciation & Amortization | $5,614 | $5,172 | $4,552 | $2,586 |
| EBITDA | -$109,038 | -$51,916 | -$117,064 | -$145,483 |
| % Margin | -168.5% | -39.8% | -374,748.7% | – |